Three late stage programs are based on dasiglucagon, a stable glucagon analog: positive Phase for treatment of severe hypoglycemia in diabetes with anticipated new drug application (NDA) submission within the coming year; Phase 3 ongoing for treatment of the rare pediatric condition, congenital hyperinsulinism; and a Phase 2b study planned for use in dual-hormone fully automated pump therapy for management of type 1 diabetes.